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Abstract 
The present Work Project highlights the problem of the market disequilibrium existing 
in the pharmaceutical industry, caused by the coexistence of both: overproduction 
(implied destruction costs), and the fact that many patients have insufficient purchase 
power. This Work Project develops a two-phase methodology to recognize best 
practices of social enterprises. The first phase is the elaboration of a questionnaire and 
the second is a one-on-one interview. The objective was to understand the range of 
action, the mission, and the structure of social enterprises. The research has shown that 
different social fields impose context-specific structures, a tendency to operate in a 
regional scale and seeking for social benefits rather than profit seeking.  This Work 
project prepared a co-operative business model, reinforced by academic literature, 
attempting to reduce waste and correct market disequilibrium by reallocating products 
to underprivileged. The business model is designed under the premise of fostering 
sustainability and assumes responsibility to formulate a solution for market 
disequilibrium in different fields. 
Keywords: Social enterprise, Pharmaceutical Industry, Social bank, Redistributive business models. 
1. Introduction 
 The present Work Project intends to illustrate the problem of market disequilibrium 
in the pharmaceutical industry: the coexistence of both overproduction, which 
implicates destruction costs for laboratories, and the fact that many patients do not have 
the purchase power to acquire essential pharmaceutical products. The Work Project 
intends to reduce market disequilibrium and develops a model that re-balances this 
market through the concretization of win-win relationships embebbed with strategic 
partnerships and targets an empowerment of lower layers of society. 
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Article 25 of the universal declaration of human rights claims that: “everyone has the 
right to a standard of living adequate for the health and well-being of himself and of his 
family, including food, clothing, housing and medical care and necessary social 
services”. The pharmaceutical industry is essential to the welfare of the population and 
is entitled for providing goods and services considered vital. It is responsible for 
developing and producing pharmaceutical products for human and animal usage. This 
field assumes great relevance for society‟s welfare, as a healthy condition of citizens 
enhances lifestyle, satisfaction and lifelong productivity (Burton, 1999).  
During the last decade, the impoverishment of many urban areas experienced the 
emergence of various innovative initiatives (C. Borzana & J. Defouny) and it is possible 
to identify several social enterprises operating in different fields (e.g. food Industry, 
scholar books, etc.). The goal of this type of social enterprise is the association of two 
social weaknesses that coexist in the same market: overproduction on one side and lack 
of access to basic services among lower layers of society. In order to strengthen policies 
to support the underprivileged to reduce barriers to people‟s access, the delivery of basic 
services is a key step for poverty reduction (Berry, 2004) and several social enterprises 
are focused on creating a linking channel to overcome or, minimize this disequilibrium. 
The scope of the present Work Project is limited to solutions that correspond to the 
needs of the Lisbon area, while the business model presented intends to harmonize the 
economical disequilibrium existing in the pharmaceutical market by aiming the 
reduction of waste and its allocation among a social system that will provide access to 
pharmaceutical products to underprivileged and providing guidelines for future 
interventions on this field. 
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2. Problem Identification  
 Economic downturn and globalization pressure have diminished the ability of 
governments to deliver effective social services (Ketl, 2000). The public state has not 
succeeded in resolving problems of poverty and social exclusion that have increased 
throughout recent period (Mendel & Nogales, 2009). Social concern is determining new 
approaches for value creation (J. Dees, 1998) and the development of business models 
following resourced-based-view logic. The legal framework of the pharmaceutical 
industry follows highly regulated requirements that can be seen through certificates of 
quality or certificates of accomplishment corresponding to good distribution practices
1
.  
It is important to remember that pharmaceutical products are exposed to systematic 
quality control tests due to their vitality in society and some can only be administrated 
according to specific medical prescription which confers a specific characteristic to this 
market. As a consequence, the final user has no influence during the decision process 
and the price of the prescribed product might be out of his purchasing capacity. A wide 
range of spill-overs may elapse from this situation: (1) ideological, as it privies citizens 
from a common fundamental human right, (2) social, as the lack of access to health care 
decreases the quality of life and (3) economical, as it exponentially increases hospital 
costs
2
.  
According to an estimate (Internal Report Bank of given goods) performed by Entrajuda 
(Association for Support of Nonprofit Institutions), about 20% of Portuguese population 
is under a condition of poverty threshold, meaning that they receive the minimum level 
of income deemed adequate (Ravallion & Martin, 1992). Another study (Internal Report 
                                                          
1
 This fact must be recognized by the national authority of medicines and health products (Infarmed) 
2
  More patients admitted for lack of medicines, Jornal Sol, 2
nd
 February, 2012. 
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Food Bank
3
) reveals that 40% of the answers (the answers belong to people aided by 
institutions – people in need) cannot afford pharmaceutical products or must postpone 
its purchase due to financial reasons. Great Lisbon area has around 2 Million people, if 
it is considered that 20 % are under poverty threshold it represent 400.000 people. 
Assuming that 40% of them delay their treatment for financial reasons, the final 
dimension of the problem, in Lisbon area, respects around 160.000 people.  
The overproduction of pharmaceutical products is, in contrast, still one of the major 
problems in this industry. An existing commercial practice imposes that pharmaceutical 
products can no longer be commercialized if they reach 6 months prior to expiry and 
are, thus, removed from the market. Some of these products are posteriorly destroyed. 
This process carries increased costs for laboratories and other related health care agents. 
Although it was not possible to determine the overall dimension of this problem, some 
numbers provided by Profarin (Portuguese wholesaler) show that near 0, 3% of total 
units‟ traded (See Appendix 1) are posteriorly destroyed. The previous fact reveals that 
a considerable amount of products are still in good conditions when sent to destruction, 
and could be used, at no increase cost for the supply side (in fact it decreases destruction 
costs and reduces the risk involved), to meet underprivileged people needs. 
These facts prove per se the existence of market disequilibrium and provide an 
incentive to intervene. Through the settlement of logical business reinvention, it is 
feasible to propose a business model that succeeds in harmonizing the market 
disequilibrium over the Pharmaceutical Industry. The arising awareness of this market 
disequilibrium and related positive feedbacks from health care agents in Portugal (see 
Appendix 3) means that the problem is not being neglected, but so far it subsists.   
                                                          
3
 Internal report of the food bank reveals that it serves 74.106 people in Lisbon. 
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3. Benchmarking  
3.1 International Overview  
 The increasing awareness of societies has derived from the triggering of social 
enterprises, as it has provided an impulse for the creation of social targeted institutions 
in various fields of action. This growing imperative to address poverty has led to a 
number of new broad-based proposals from the developed world (Lodge, 2002) and 
drives initiatives that involve large corporations such as Pfizer or Merck aiming for 
good reputation as result of corporate social responsibility strategies. Despite this fact it 
is more likely to find non-governmental organizations operating in this field.  Operating 
at a multinational level are for example the Medicine Bank, the Global Hand, and MJKJ 
Foundation , that operate under the premise that “third world countries often lack the 
financial means and access to medical supplies necessary to sustain or improve their 
quality of life” (MJKJ Foundation) and perform this harmonization process at a global 
scale. There are several organizations that prove to re-balance the health care market 
from a transnational level, e.g. the United Nations has a plan for drugs and food supply 
in case of war or natural disasters.  
At a national level it is possible to find in other countries numerous organizations that 
attempt to re-balance pharmaceutical market, like the pharmaceutical bank in Chile or in 
Italy
4
. In Brazil, the field experience of Bank for Management and Sustainability states 
that the pharmaceutical bank is the one that presents higher and more urgent demand.  
3.2 Portuguese Overview  
 The research performed allowed to compile a list of 26 social enterprises operating in 
Portugal that commonly attempt to provide the harmonization process described in 
                                                          
4
 Italian Pharmaceutical Bank was a pioneer in this field and both Spanish and Portuguese banks are a 
replication of this business model. 
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several social fields that (see Appendix 4). The specific inherent tasks of these social 
enterprises vary from their method of collection, logistics, handling, mission and 
delivery systems. This result in a wide range of structures that vary on: human resources 
employed, structure, commodity stocking needs and sustainability of the specific core 
business. Furthermore these initiatives can operate at regional or national level and 
perform this balancing effect at different scales (see Appendix 3 for practical examples). 
It is possible to observe in the specific example of the pharmaceutical industry the 
appearance of local initiatives that attempt to re-establish the market equilibrium.  These 
attempts range from local pharmacies level, local municipalities and political parties 
(e.g. Municipality of Santa Comba Dão or the Community Center of Carcavelos). These 
attempts relay the collection premise on withdrawal of pharmaceutical products from 
the outside of the commercial circuit (e.g. patient died or changed treatment) and the 
product is „donated‟. These enterprises in Portugal failed to target the biggest portion so 
far, as they only target the consumer side, rather than the industrial sector. Despite these 
attempts are praiseworthy, the methodology goes against the decree law number 
176/2008 of the Statute of Medicine
5
 as it is impossible to certify how products were 
handled outside of the commercial circuit (pharmaceutical product‟s lifecycle and 
respective commercial circuit can be seen in Appendix 5).  
In the recent years, two different models arised under national context: the appearance 
of the Pharmaceutical Bank, in 2009, which has the mission to aid people in need 
through the collaboration and involvement of communities and an appeal for donation – 
it targets pharmacy users, as they are induced to buy products for charity in loco –, and 
                                                          
5
 Decree law number 176/2008 of the Statute of Medicine - transposing the European Union legislation 
which revision marks a profound change in the field of medicine and impedes any pharmaceutical product 
that left the commercial circuit to be donated.  
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the creation of the new Medicines Bank, December 2012, as consequence of the 
Portuguese Social Emergency Plan
6
 release by the Government. This last initiative has 
been launched in Lisbon in an exclusive partnership with the Holy Houses of Mercy and 
proves to drain industrial overproduction (withdrawing pharmaceutical products before 
they are destroyed after being removed from the commercial circuit) to serve elderly in 
need (no purchase power) of essential prescription drugs. Both models comply with 
legal framework and technical requirements imposed by Infarmed. The above 
mentioned cases represent several cases of social enterprises that attempt to re-distribute 
pharmaceutical products, onto different levels, chasing the goal of harmonization 
market disequilibrium in the pharmaceutical industry.  The recent activity and results 
obtained by both initiatives reveal the need to act urgently to solve this problem. 
4. Literature Review 
    Social enterprises are part of a new welfare mix in which both governments and 
citizens cooperate in the co-design of new forms of social service provision (Ascoli and 
Ranci, 2002). This typology seeks to reverse policy as regards the state‟s role in the 
delivery of health and social services (Duff, 2011). Social enterprises present particular 
strong points compared to other types of organizations notably as regards the 
mobilization of resources, satisfying certain needs and fighting social exclusion 
(Borzana & Defouny, 2004). This trend seems to be redefining the obstacles that have 
prevented businesses from providing services to lower layers of society. Schumpeter
7
 
refers that entrepreneurs are adjusting their business models to deal with the age of 
austerity. This is reinforced by a higher awareness that the bottom of the pyramid 
                                                          
6
 This plan (from 2011) states that pharmaceutical products that were previously outside of the 
commercial circuit by less than six months to complete its expiry date will be distributed freely to elderly 
through accredited institutions safeguarding rules of legal security complying with legal framework 
7
 The Bottom of the pyramid. The economist, 23
rd
 June, 2011. 
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market (BOP) is achieving, BOP in the context of developed economies means the 
relative poverty that is experienced by the lower end of the income scale (Brueckner, 
2010). This socio–economic derivation presents negative consequences for health state 
(Townsend, 1987).  In order to create locally embebbed BOP strategies, it is firstly 
important to have a deep dynamic understanding of the specific local context 
(Chambers, 2007) and act accordingly. It is possible to identify various social 
enterprises that lead for inspired models of value creation (Selos & Mair, 2005) trying 
to solve neglected social problems by using alternative and innovative approaches, 
transforming mentalities and societal dynamics, empowering and involving community 
and stakeholders (Dees, 1998). Social enterprise is based on the concept of aiming to 
serve members of one community rather than generate profit. This type of enterprise is 
characterized by a sector where organizations are established by people on a voluntary 
basis to pursue social, charitable and community goals.  
The creation of a pharmaceutical bank is embraced to social benefit it is possible to 
identify and frame this Work Project in a co-operative business model according to the 
definition provided by the UK Department of Trade and Industry. A Co-operative 
business model can be defined by its internalized social orientation, democratic 
governance (Brown & Murphy, 2003) and entrepreneurial activity intrinsically related 
to philanthropic roots (Duff, 2008), it is activist-friendly and revolution-ready (Shaffer, 
2005). Chesbrough (Chesbrough, 2006) proposes a six step formula for the elaboration 
of a business model: (1) articulate the value proposition, (2) identify the market 
segment, (3) define the structure of the value chain, (4) estimate the cost structure and 
(5) describe the position of the firm within this network in order to (6) formulate a 
dynamic competitive strategy. This Work Project will propose in section 8 a specific 
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business model for the creation of a pharmaceutical bank, following the 6 proposed 
tasks and contextualize the model to the specific needs of the pharmaceutical industry. 
5. Methodology 
In order to formulate the business model, the Work Project develops a specific 
methodology to understand best practices of social enterprises operating in several 
fields. In numbers, the research allowed to observe the existence of 26 social enterprises 
in different fields, 21 operating nationally. The first phase of the methodology was the 
elaboration of a questionnaire that has been delivered to 15 enterprises (only 14 
respondents). This number characterizes over 50 % of the entire population, which 
grants a solid base for benchmarking. The purpose of this questionnaire is to identify the 
best practices and to filter key activities
8
 for a better understanding of the business 
model and key resources used.  
The second phase was performed through a visit and a one-on-one interview to 6 
institutions, from which 5 have been performed to national enterprises. This number is 
result from a mixed analysis of the first phase in what regards: mission, range of action 
and the classification of the commodities. The second phase is a deeper market research 
in order to strengthen the business proposal and provide a real-insight analysis. The 
objective is to identify how these structures are organized and what are the inherent 
inbound and outbound logistics, infrastructures needed and human resources employed. 
It intends similarly to understand the methods used by social enterprises to address both 
recipients and donors. The questionnaire (Appendix 6) and results of both phases of the 
                                                          
8
While discarding social initiatives from a deeper analysis, it is important to mention that it does not mean 
that qualitative rating is low but that some structures  social enterprises are more adequate to the business 
model proposed, due to its intrinsic conditions (essential market, commodities, context and approach).  
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methodology were treated and categorized (see Appendix 7 and 8). In order to 
benchmark the model proposed according to best-practices it is important to take into 
account the theoretical background of section 3. With a purpose of a more dynamic and 
specific approach, several contacts were performed with both Spanish and Italian 
pharmaceutical banks, but did not proceed as it was not possible to reach relevant 
information.  
6. Value Proposition and Strategic Objectives 
 The Work Project intends to provide a co-operative business model that attempts to 
reduce waste of pharmaceutical products and correct the market disequilibrium in the 
pharmaceutical Industry by reallocating products to underprivileged people. This 
proposal is based on the best practices and adapted to input provided by the models 
researched. The result is the creation of a hybrid structure that is able to drain the 
overproduction from the industry sector at the same time that effectively appeals for 
individual donation and creates awareness for the problem (e.g. through the Journey of 
drug-donation) engaging communities and aiming people in need, reaching greater 
social benefits. Furthermore, the business model promotes a more equitable access to 
basic services and enhances commitment for social causes, on a long term perspective 
these efforts attempt similarly to teach communities to donate instead of waste.  
The impact in the overall market is hard to measure, but an increase on basic services 
access across lower layers of society is likely to increase overall productivity and 
distress financial pressure for other demand and improve lifestyle, alleviating 
disadvantaged population 
 
(Amit & Zott, 2011). In parallel, this Work Project intends to 
provide, both Portuguese Medicine Bank and Portuguese Pharmaceutical Bank, 
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pathways for the improvement of their mission and provide a subset of activities and 
specific strategies that reinvent the value capturing logic within the pharmaceutical 
industry. The next section of this Work Project is to identify key performance indicators 
and best practices of the social enterprises studied and understand their modus operandi. 
7. Data Analysis & Key Performance Indicators 
7.1 Mission  
Typically, these social enterprises collect from the supplier side and deliver over the 
demand side which leads these enterprises to be named „banks‟. The mission of these 
enterprises is often related to an attempt to reduce waste or to improve community 
sharing, correcting market disequilibrium for basic services. Social banks differ from 
commercial banks as they do not operate under a profit-earning goal. These banks 
instead of commercial banks, rather than profit seeking, aim to alleviate non-
development conditions in society.  
Best practices usually follow a common pattern setting for the structure of enterprises: 
(1) elaboration of a direct collection process of surplus on the supply side of the market; 
(2) or an appeal for consumer donation (3) and the creation of an internal logistical 
structure to process collected products. The final step (4) is the handling, distribution 
and reallocation of commodities among aided institutions. 
7.2 Market Segment 
The results of the methodology display the tendency of social enterprises to operate 
in a regional scale in order to provide more efficiency while providing their services. 
Social enterprises are mainly divided in the following functions: Financial and 
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Administrative support; facilities and equipment needed; public relations and external 
image; volunteer coordination; stocking and collection functions; distribution and 
technical (in case it is needed). This type of social enterprises typically locate 
themselves as an intermediary from the industry by rearranging the flow chart of the 
market, avoiding waste, and reallocate to institutions that serve people in need.  
7.3 Defining Structure of the Value Chain 
 Several tasks are required to be performed internally after the collection process 
and before its delivery to aided institutions: (1) reception of the product; (2) subdivision 
by segment of commodities and by hangar, (3) assisted by bureaucracy and back-office 
activity while (4) arranging the orders, and (5) preparation of respective shipment.  
Concerning Human Resources department it was noticeable the fact that paid personnel 
does not depend on the business volume but rather on the tasks necessary to perform the 
service. It is common to find volunteer work force these structures in all phases of the 
process as an attempt to engage communities and reduce costs. Governance is also an 
important factor to benchmark to propose an effective system of administration but the 
research process was not successful in this field as it was not possible to reach relevant 
information, meaning that does not provide an insight to any particular system of 
administration. It is feasible to recommend the governance to be performed by a board 
of volunteers and align the mission and value proposition to the present structure 
(Maranville‟s, 1999), granting transparency and independency in the decision process. 
Theoretical background reveals a tendency for a variety of requisites of the board in 
order to correctly address particular circumstances of each individual enterprise 
(Bradshaw, 2000) that overcome other types of leadership in social enterprises. 
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7.4 Estimate Cost Structure  
The emergence and rapid growth of social enterprises has created a new financial 
market to respond to the need for capital to finance these enterprises (OECD Report) 
and also for financial innovation, developing a customized financial sector (Nicholls 
and Pharoah, 2007). It is unlikely to find social enterprises performing such type of 
activity and charging for the provided services to users, although they exist
9
.  
The tasks mentioned in the previous section generate all range of back office supplies 
that present regular residual costs. It was possible to observe, given the specific 
conditions of social enterprises, large differences on their cost structures. The need for 
equipment and handling processes of collected products implies the need for 
compulsory human resources that by principle are volunteers, although many exceptions 
exist. A common setting for these enterprises is the continuous search for diminishing 
costs following a resourced-based logic which guides social banks to diverse their 
strategies of fundraising. Typically this activity results in the generation of a network of 
Maecenas that directly funds office suppliers, Human Resources and essential costs. 
The key for this challenge is to create dynamic partnership and diverse fundraising as 
premises to a consistent financial solution and financial sustainability. 
7.5 Position of the Enterprise within this Network  
A well designed business model is likely to be highly situational and its processes are 
likely to involve iterative processes, while new business models can both facilitate and 
represent innovation (Teece, 2010). Based on the cyclicity of the collection process it is 
possible to fragment strategies of different social enterprises as it is hard to compare the 
                                                          
9
 Note: Animal blood bank charges a fee to owners of recipient animals: and the current initiative of the 
pharmaceutical bank charges a fee of 60€ to adherent pharmacies on the Journey of drug-donation. 
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time needed to redistribute food (perishable commodity) to the time needed to 
redistribute one piece of clothing (nonperishable) and the handling provided cannot also 
be compared while treating different commodities as a book (no handling needed) or a 
computer (needs technological supervision, repair, and also presents higher regular costs 
to the bank). Concluding, different sectors impose different structures and bottlenecks. 
It is important to coordinate activities with donors and recipient institutions to align 
them with managerial requirements on what concerns: tracking and delivery systems, to 
proceed for a sustainable partnership. Common practices suggest that the recognition of 
a partnership assumes the existence of a first contact and one visit to the recipient 
institution, to confirm all regulatory requirements. Once these tasks are all overcome, a 
protocol is signed between entities. Best practices impose also the alignment of these 
institutions and the final result is a straight-forward network that creates and captures 
the added value generated by the model, respecting all legal frameworks. 
7.6 Formulation of a Competitive Strategy  
A model that seeks both efficiency and awareness by attempting to collect both 
individual donations and industrial overproduction is a reference for other banks. This 
hybrid strategy intends to reduce waste while at the same time promotes the feeling of 
charity and raises awareness for the problem in question. The majority of the models 
screened revealed that they target only one side, except the exemplary case of the food 
bank that will be taken into consideration in the formulation of the business model.  
One of the challenges that usually face these initiatives is the creation of (sustainable) 
partnerships. Best practices suggest the elaboration of a list of possible arguments for 
kick-starting one relationship with key partners. Through the exploration of win-win 
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situations as (1) the appeal for a donation receipt
10
, (2) strain for a common effort on 
reduction of product destruction and implied costs, (3) the creation of friendly 
communities through networking and involvement of the organization that increases 
brand reputation and visibility – these strategic arguments have largely reached positive 
results. Other factors that can help to involve donors are: corporate social responsibility 
policies, brand recognition and awareness that may arise from this participation.  
8. Business Model Proposal 
The implementation of a Pharmaceutical Bank ought to start in a relative small area 
(regional level). Attending to the concentration of pharmaceutical laboratories; stocking 
possibilities and proximity to wholesalers which guarantees rapid transportation, it is 
possible to choose one area to pilot this project.  In order to propose a valid test in a 
small scale for a controlled experimentation (that allows a more efficient monitoring 
activity), the area of Lisbon
11
 is, in consequence, the most adequate region for the pilot 
of the pharmaceutical bank. The implementation of a pharmaceutical bank (see 
appendix 4 to understand the positioning of the model) implicates the proactive 
participation of pharmacies in order to return products quickly once they reach 6 months 
to expiry date. Laboratories are also entitled to donate their surplus in a regular-basis 
(section 7.6 explains how to address this challenge). To simplify this process, Infarmed 
must also grant efficiency and promptness in accepting all donation processes.  
For a purpose of efficiency and differentiation from previous models, the business 
model targets all types of pharmaceutical products: generics; medical devices, drugs 
                                                          
10
 This payment process favors donors as the value of the transaction can be deduced from taxes. This 
compensation on taxes represents a monetary added value for the donor organization, according to the 
decree law 108/2008 of the statute of tax benefits (See Appendix 9 for the decree law). 
11
 The level of demand and greater awareness were also taken in account while formulating this choice. 
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subject to prescription, drugs non-subject to prescription and also relevant 
dermocosmetics. This statement intends to create a dynamic structure that aids people 
who cannot acquire essential products for specific diseases or subclinical situations, 
meeting the goals proposed as it reduces waste and reallocates collected products 
originating societal surplus. Reducing waste is desired at the maximum level possible in 
order to impose efficiency levels as tracking devices of pharmaceutical bank activities.  
The business model here proposed settles a hybrid structure that seeks both parts of 
collection: individual donation and draining of the overproduction. In case this 
implementation succeeds: both demand and supply curves for pharmaceutical products 
are steady which implicates that this process only occurs if it exists demand and that this 
specific demand cannot be satisfied through traditional market. The society as whole 
benefits both economically, as laboratories reduce their risk and costs and obtain 
financial compensations, and societal as lower layers of society meet their needs and 
improve their health state and consequent spill-overs as defined in section 2. It is 
important to restrain the quantity of donations occurred in order to avoid abuses from 
laboratories. At this stage it is fundamental to define that the pharmaceutical bank is not 
only responsible for collecting the pharmaceutical products as it is also responsible for 
allocating them accordingly, and on time, among recipient institutions complying with 
the legal framework (e.g.  Good distribution practices and Infarmed approval). 
It is utopic to plan zero-cost for all the activities performed by the bank but a continuous 
search for cost reduction is imperative. Pharmaceutical bank is advised to fundraise 
among strategic partners and follow a continuous search for alternative funding: pro-
bono services and concession of donation-receipts (see Appendix 9 for legislation): 
management system; volunteer work, transportation, stocking, back-office supplies, 
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communication costs with partners, handling material and others in order to optimize a 
low cost strategy. A charged fee from pharmacies, that participate in the annual journey 
of drug collection, like is in practice by the pharmaceutical bank in Lisbon is 
recommendable to finance back-office activities. It is important to create engagement 
from all the involved parties through the settling of clear objectives and development of 
sustainable relationships. This process intends to coordinate and simplify the 
relationship between the enterprise and the institution and must guarantee that recipient 
institutions are providing services adequately. It is important to note that only valid 
institutions can receive products – as the delivery phase to the final patient must be 
supervised by a legal pharmacist.  
Best practices (e.g. food bank or bank of equipment) demonstrated the benefits of a 
well-designed management system fully integrated capable of managing all activities 
like: delivery periodicity and timings, stocking units and references, volunteer 
coordination, partners‟ priorities evaluation and respective tracking activities, main 
needs and services provided. It is recommendable the usage of an effective management 
system which implicates high efficient back-office activity on synchronized activities 
and in constant communication with all institutions, donors and distributors. It is 
fundamental that this system is updated and coherent with reality in order to support its 
mission. This last aspect assumes relevance in the prevention of fraud and abuses. 
Distribution plays a pivotal role in the process and the process is recommended to 
follow traditional channels (already in usage) of the pharmaceutical products and the 
possibility of using a segment of a loft must be considered as an attempt to reduce costs. 
This small loft can be a compartment inside the facilities of a wholesaler in Lisbon (e.g. 
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Profarin) whereas the facilities fulfill all law requirements already and thus present no 
relevant increased costs.  
The pharmaceutical bank does not perform a quality test on collected products as they 
are assumed to be appropriate (note: the products did not leave the commercial circuit) 
until their expiry dates and meant to be in perfect conditions of safety and quality. The 
pharmaceutical bank is responsible for labeling different categories of products. After 
the products are labeled they are posteriorly: registered, endorsed, prepared and ordered 
for redistribution. Perishable products have a faster chain model and the expiration date 
must be taken into consideration while categorizing the products. The existence of many 
references imposes its division by several smaller hangars to divide them by categories - 
this separation should segment pharmaceutical products either by active pharmaceutical 
ingredient or according to the relevance of treatments in order to create a flow while 
preparing institutional packages, avoiding the creation of bottlenecks. Despite that 
pharmaceutical products come in full packages it is recommended to separate it in 
mono-doses according to the single service being provided
12
 respecting good practices. 
The previous fact and best practices suggests that pharmaceutical products should be 
picked up directly by aided institutions, in case it is not possible, transportation to 
recipients is dealt case by case with institutions in order to minimize costs.  It is 
important to remember that best practices suggest the validation of all partnerships to 
align them with the mission and structure. Empirical models suggest relaying the 
activities performed by the social enterprise on volunteers, to perform all range of tasks. 
Recruitment and volunteer coordination must be adapted to the bank‟s embedded 
culture and aligned with the mission. The bank is supposed to recruit adequately to 
                                                          
12
 It is important to highlight that the model delegates for institutions the administration and regulation of 
the products given, although feedback is required concerning the destination of the products collected. 
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avoid lack of workforce needed to guarantee the service is provided in the required 
deadlines and respecting safety features. Appendix 2 proposes a team dedicated to the 
specific tasks including indicatory tasks.   
This Work Project follows a mission-driven concept and a social entrepreneurial 
philosophy as it expects to explore gaps left by regulations or rules (Welter, 2010) in 
order to reach greater social benefits. The present business model proposes to reach 
50,000
13
 pharmaceutical products, per year, in Lisbon area, and redistribute it among 
around 100 direct aided institutions
14
. This process implies the creation of stable 
partnerships with: laboratories, wholesalers, pharmacies, distributors and institutions. 
The overall impact given the characteristics of pharmaceutical products is difficult to 
measure but it will ultimately empower these institutions. A sustainable solution will 
reduce overall health care costs in this segment and optimize the management system of 
the society as a whole, at no relevant increased cost for society. 
9. Conclusions 
This Work Project presents an evaluation of the pharmaceutical industry in Portugal 
and highlights the importance and urgency of society‟s needs for pharmaceutical 
products. The work project intends to prove that this problem is a social imperative in 
the pharmaceutical industry and proposes a business model that attempts to empower 
the overall society, benchmarked on several social enterprises with expertise in different 
social fields (social enterprises operating internationally, nationally and at regional local 
level) and based in academic literature. It is important to refer that the business model 
proposed meets all legal, contextual and financial requirements. Although the project is 
                                                          
13
 Circa 20% of the products sent to destruction, per year, in one single institution (Profarin).  
14
 There are over 1,000 social institutions in Lisbon area (target = 10% of the entire population). 
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centered in Lisbon, it must seek to collect surplus at a national level and prepare a trail 
for expansion to other urban centers to meet local demands. In case the business model 
proves to enhance social benefits to local populations it is important to provide 
suggestions for the replication of the phenomenon. One key to foster its dissemination is 
through reliability on local entrepreneurship, given the specific knowledge and local 
connection to the networks (Banerjee & Duflo, 2006), suggesting the creation of a 
Federation, responsible for their tutoring and coordination, that homogenizes and 
aggregates pharmaceutical banks and acts as one voice. 
To conclude, the process is designed under the premise of an on-going necessary 
reevaluation to foster sustainability and it assumes also responsibility for gathering data 
to formulate more elaborated future approaches to solve these social problems derived 
from market disequilibrium in different areas, which implies that if the model succeeds 
it becomes potentially attractive and re-usable in different social fields. 
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Appendixes 
Appendix 1 – Profarin numbers concerning destruction of pharmaceutical products 
Period Jan-May  2012 2011 2010 
Units returned 85.791* 237.126 240.501  
*Only 5 months  considered 
 
Appendix 2 – Recommendation of volunteer force for the Pharmaceutical Bank  
Function Job Task 
Secretary  
Provide administrative support and prepare office supplies, together with the head of the loft is responsible 
for monitoring the management system, responsible for the emission and handling of invoices
15
. 
Public relations  
Actively communicate with laboratories, provide relevant press releases to raise visibility and to raise 
sponsorships (for the sustainability of the bank). 
Head of loft  
Responsible for receiving, labeling and shipment/delivery of pharmaceutical products to recipient 
institutions – these activities are assisted by volunteer work to organize and distribute collected products. 
Account manager  
Responsible for the acceptance of institutions, further coordination and communication, responsible for 
volunteer coordination and regular monitor-visit to institutions. Responsible for collecting data for the 
management system prioritization. 
Pharmacist  
Responsible for regulatory affairs involved, evaluation of patients being served, guarantee of certificates and 
features, labeling the pharmaceutical products collected and responsible for technical communication with 
pharmaceutical labs. 
                                                          
15
 Invoices should include all data concerning the pharmaceutical bank, the recipient institutions, the 
quantities shipped, references, batch of validity and respective weights.  
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Appendix 3 – Health Care entities feedback about: the problem and appearance of social  
 
 
 
 
 
enterprises on this field 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4 – Screen of Social Enterprises in Portugal performing  
Animal Blood Bank Blood Bank  Humana Portugal 
Bank for Given Goods Sperm Bank Movement for used Books 
Bank for Social Useful Goods Book Bank Organ and Transplantation Bank 
Bank of Building Materials Cell Bank Pharmaceutical Bank* 
Bank of Collective Meals Clothing Bank Residuals Bank 
Bank of Furniture Computer Bank School Material Movement 
Bank of Human Tissue Databasis Bank ReFood 
Bank of Public Works Equipment Bank Umbilical Cord Bank 
Bone Marrow Bank Food Bank Volunteering Bank 
* Similar business models in Spain, Italy, Portugal, Brazil and Chile. 
 
Entity Title Link 
ANF (national association 
of pharmacies 
ANF considers positive the creation of a medicine 
bank 
www.rtp.pt/noticias/index.php?article=467709&tm=2&layout=123&vis
ual=61  
Infarmed (national authority 
of medicines and health 
products) 
Underprivileged especially elderly can already recur 
to the medicines bank  
www.aeiou.pt/quiosque/banco-de-medicamentos-e-formalizado-hoje  
Apifarma (represents more 
than 120 pharmaceutical 
laboratories) 
APIFARMA collaborates with the creation of a 
solidarity medicine bank  
www.apifarma.pt/salaimprensa/noticias/Paginas/APIFARMAcolaborana
cria%C3%A7%C3%A3odaBancodeMedicamentossolid%C3%A1rio.asp
x 
Social Security Protocol for the formalization of the medicine bank 
www.cmjornal.xl.pt/detalhe/noticias/nacional/saude/protocolo-para-
formalizacao-do-banco-de-medicamentos 
Holy house of Mercy 
Medicine bank for the underprivileged elderly will be 
activated in December  
www.portugal.gov.pt/pt/os-ministerios/ministerio-da-solidariedade-e-
www.seguranca-social/mantenha-se-atualizado/20121109-msss-banco-
do-medicamento.aspx  
Medicine Bank 
Medicine bank for free 
www.cmjornal.xl.pt/noticia.aspx?contentID=AB69D625-5E63-47A4-
8D0A-1E5E630AB23A&channelID=00000021-0000-0000-0000-
000000000021 
Medicine bank for the underprivileged elderly will be 
activated in December  
www.apifarma.pt/Documentos%20ENews/LUSA_BancoMedicamentos
_09112012.pdf 
www.diariodigital.sapo.pt/news.asp?id_news=600916 
AAF 
Banco Farmacêutico promoveu recolha de 
medicamentos 
www.ordemfarmaceuticos.pt/rof96/files/assets/basic-html/page49.html  
Pharmaceutical Bank Website current initiative pharmaceutical bank www.bancofarmaceutico.pt  
  
  
Other related news Title Link 
Almofariz award  Almofariz award goes for the pharmaceutical bank www.o-povo.blogspot.pt/2012/05/premio-almofariz-para-o-banco.html  
Medicine Bank 
Medicine bank has collected 11.000 packages to 
underprivileged elderly 
www,sicnoticias.sapo.pt/vida/2012/12/01/banco-de-medicamentos-ja-
tem-11-mil-embalagens-para-idosos-carenciados-diz-ministro 
Social emergence plan Medicine bank is formalized today 
www.mmclip.com/Pdftmp/11549273_4_2151_apifarma.pdf  and   
www.mercadosocialarrendamento.msss.pt/docs/programa-de-
emergencia-social.pdf  
 
Examples of previous national initiatives to redistribute health 
in Portugal 
Link 
Municipality of Santa Comba Dão – creation of a medicine bank 
www.cm-santacombadao.pt/index.php/pt/informacao-
municipal/noticias/880 
Community center of Carcavelos www.centrocomunitario.net/ 
Municipality of Cascais www.cm-cascais.pt/area/promocao-da-saude 
Individual pharmacies‟ initiatives all over the country N/A 
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Appendix 5 – Pharmaceutical Industry business scheme 
  
Appendix 6 – Adapted version of delivered questionnaire to Social Enterprises 
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Appendix 7 – Summary of the answers of the questionnaire  
Entity Commodities Mission Observations 
Animal Blood Bank Non-perishable 
Guarantee an excellent product prevenient from healthy 
and controlled animals. 
National level 
Bank for social utility goods Non-perishable 
Tackle basic needs according to a rapid, efficient and 
broaden approach. 
Regional level 
Bank of given goods Non-perishable 
Double objective: effort on reducing waste and empower 
work of NGO's and environment   
National level 
Bank of steam cells and 
umbilical cord 
Non-perishable Reduce Waste  National level 
Bio-bank – IMM Non-perishable Contribute to public health promotion and society welfare Currently in the starting phase  
Bone Marrow Bank 
Non-perishable 
Tackle basic needs according to a rapid, efficient and 
broaden approach 
National level 
Equipment Bank Non-perishable Reduce Waste Regional level 
Food Bank Portugal (Lisbon) Perishable  Reduce Waste  
Regional level.  
Federation at national level. 
Movement for used books Non-perishable Reduce waste. Reuse is preferable than recycle.  Regional level 
Pharmaceutical Bank Brazil Perishable  
Help poor people by providing medicines and health 
products 
Regional level 
Pharmaceutical Bank Italy Perishable  
Help poor people by providing medicines and health 
products 
Regional level 
Pharmaceutical Bank Portugal Perishable  
Help poor people by providing medicines and health 
products 
Regional level 
Pharmaceutical Bank Spain Perishable  
Help poor people by providing medicines and health 
products 
Regional level 
Sperm Bank Perishable  
Provide excellence in medical education about infertility 
and donor sperm 
International level 
Note: The food bank, equipment bank and bank of given goods belong to the Association Entrajuda and operate in similar premises 
 
Appendix 9 - Statute of tax benefits on Corporate Income Taxes 
Corporate Income Tax (IRC) – Donation of non-food products can be deduced from IRC based on the article 62 of 
the statute of tax benefits: donations are considered costs or exercise losses until a limit of 8/1000 of sales business 
volume of the donor firm  
 
Source:   www.portaldasfinancas.gov.pt 
 
 
 
 
Appendix 8 – Summary of interview phase 
Entity Human Resources Facilities Equipment 
Food Bank Yes, 1 per function 1 loft  
Machinery, leasing of vans, back office 
equipment 
Bank for social utility goods 3 workers and 12 volunteers 1 office and 1 loft Leasing of vans and office supplies at pro-bono 
Bank of given goods 8 workers and 40 volunteers 1 office and 1 loft Machinery, back office equipment and a van 
Biobanco – IMM 8 workers 
1 laboratory and related 
facilities 
Informatics hardware, archive and processing 
equipment 
Equipment Bank 8 workers and 40 volunteers 1 office and 1 loft Machinery, back office equipment and a van 
Portuguese Pharmaceutical 
Bank  
1 part-time worker Not needed   Outsource of services at pro-bono 
